Tech Company Financing Transactions
Sorbent Therapeutics Funding Round
Sorbent Therapeutics, based in Sunnyvale, raised $19.2 million from Arch Venture Partners, Dow Venture Capital and Presidio Partners.
Transaction Overview
Company Name
Announced On
3/31/2006
Transaction Type
Venture Equity
Amount
$19,200,000
Round
Undisclosed
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
710 Lakeway Dr. 290
Sunnyvale, CA 94085
USA
Sunnyvale, CA 94085
USA
Phone
Website
Email Address
Overview
Sorbent Therapeutics is a biopharmaceutical company focused on the development of adaptable non-absorbed polymeric drugs to satisfy unmet clinical needs in large markets such as End Stage Renal Disease (ESRD), Congestive Heart Failure (CHF), Chronic Kidney Disease (CKD), and Hypertension.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Detlef Albrecht
Chief Financial Officer
Tom O'Neil
Chief Medical Officer
Howard Dittrich
VP - Bus. Development
Linda De Young
Browse more venture capital transactions:
Prev: 3/31/2006: SpectraLinear venture capital transaction
Next: 3/31/2006: Network Physics venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs